StockData

Iqvia vs Medpace

IQV and MEDP side by side, both in engineering, accounting, research, management, and related services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IQV and MEDP compare

Iqvia is the larger company, worth 2.3 times as much as Medpace ($42.5B against $18.3B).

On earnings, Iqvia is cheaper: it trades at 31.3× trailing earnings, against 36.2× for Medpace.

Medpace grew revenue faster over the last twelve months (20.4% versus 8.8% for Iqvia).

Medpace keeps more of each dollar of sales as profit, with a net margin of 18.2% compared with 8.1% at Iqvia.

Medpace scores higher on the StockData Score (14 against 9 for Iqvia), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIQVMEDP
Size and price
Market cap$42.5B$18.3B
Share price$257.60$653.09
Change, 1 year16.8%10.7%
Change, 5 years−1.7%211%
Beta (5Y)0.630.33
Employees93K6,200
StockData Score
Total score914 (better)
Valuation score2 (better)0
Growth score34 (better)
Performance score45 (better)
Health score05 (better)
Dividend score00
Valuation
P/E31.3× (better)36.2×
P/S2.5× (better)6.4×
P/B6.4× (better)31.2×
EV/EBITDA16.4× (better)28.9×
P/FCF20.4× (better)27.4×
PEG2.821.29 (better)
FCF yield4.9% (better)3.7%
Fair value$226.21$459.97
Margin of safety−13.9% (better)−42.0%
Growth
Revenue growth (TTM)8.8%20.4% (better)
Revenue growth, 5Y average7.5%22.3% (better)
Net income growth (TTM)8.7%19.6% (better)
EPS growth (TTM)12.9%26.1% (better)
EPS growth, 5Y average40.5% (better)31.8%
Profitability
Gross margin33.1%–
Operating margin12.8%21.4% (better)
Net margin8.1%18.2% (better)
FCF margin12.0%23.5% (better)
Return on equity21.7%118% (better)
Return on invested capital9.4%–
Financial health
Debt / equity2.41 (better)0.00
Net debt / EBITDA3.97–
Interest coverage2.8×–
Current ratio0.830.83 (better)
Altman Z-score2.218.13 (better)
Piotroski F-score66
Dividends and buybacks
Buyback yield2.7% (better)1.6%
Shareholder yield2.7% (better)1.6%
Ownership
Held by institutions95.2%88.3%
Held by insiders1.1%20.0%
Insider net buying, 12 months−$39.3M (better)−$262M
Superinvestors holding3 (better)2
Short interest, % of float1.9%6.2%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.